EUCTR2018-002564-10-NL进行中（未招募）1 期
Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoid: a phase IIa open label single arm study. - SAMP trial
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Adult (= 18 years of age) male or female patients with recently diagnosed mild to moderate localized or generalized cutaneous pemphigoid, or patients that were in complete remission without treatment that have a mild to moderate flare-up of the disease.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Women of childbearing potential without contraception; women who are pregnant or planning to become pregnant or who are lactating; patients that use systemic immunosuppressive medication; any condition which would make the patient unsuitable for treatment, or requires steroid use.
研究者
相似试验
已完成
2 期
Short-term safety, efficacy and mode of action of apremilast in moderate suppurative hidradenitis suppurativa: a randomised double-blind placebo controlled trial.acne ectopicaacne inversa10014982NL-OMON42894Erasmus MC, Universitair Medisch Centrum Rotterdam20
已完成
2 期
Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoid: a phase IIa open label single arm study.parapemphigus10014982NL-OMON49116niversitair Medisch Centrum Groningen10
招募中
不适用
PDE4 inhibitor (apremilast) in pemphigoidNL-OMON21799MCG10
已完成
不适用
Investigation of short-term efficacy and safety of 5-alpha reductase inhibitor in the patients with BPHJPRN-UMIN000025443ara Medical University200
尚未招募
3 期
Evaluation of the Safety and Efficacy of Short-term A 002 Treatment in Subjects with Acute Coronary SyndromesHeart AttackHeart Disease10082206NL-OMON34504Anthera Pharmaceuticals, Inc576